The Medical Advisor

Evidence review | Updated October 28, 2026 CagriSema and retatrutide are two investigational medicines generating substantial interest in obesity treatment. Both target multiple hormonal pathways involved in appetite, metabolism and body-weight regulation, but their mechanisms are different. CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue. Retatrutide is a single molecule that activates three receptors: GIP, GLP-1 and glucagon. Phase 3 results reported in 2026 suggest that retatrutide may produce greater average weight loss than the results reported for standard-dose CagriSema. However, there is no completed direct head-to-head trial establishing that retatrutide is superior to CagriSema. Differences in trial duration, populations, dose escalation and statistical analyses prevent a definitive ranking. Muscle preservation is another important distinction. Available body-c...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: October 2026 Quick Answer Berberine, psyllium husk, and curcumin have the best human clinical evidence among natural Ozempic alternatives, though their weight-loss effect is modest (roughly 1–4 kg over 2–6 months) compared with semaglutide's 15%+ body-weight reduction. Berberine works through glucose and lipid metabolism, not by activating GLP-1 receptors the way Ozempic does — so "nature's Ozempic" is a catchy label, not a mechanistic match. As of September 2026, prescription GLP-1 drugs have also gotten dramatically cheaper (Wegovy from $349/month, Zepbound from $299/month via manufacturer cash-pay programs) and now come in oral pill form, which changes the cost-based case for natural alternatives even as safety and sustainability concerns remain valid reasons to consider them. There are natural alternatives to Ozempic like berberine, curcumin, and psyllium husk. Oz...